$JNJ · Johnson & Johnson

Johnson & Johnson filed a quarterly Form 13F-HR disclosing its public equity holdings for the reporting period. The filing lists investments in a range of biotechnology and healthcare companies, including Adicet Bio, Cerebras Systems, Contineum Therapeutics, CVRx, Fate Therapeutics, Legend Biotech, MeiraGTx, Nanobiotix, Neumora Therapeutics, Procept BioRobotics, Protagonist Therapeutics, Rapport Therapeutics, Vor BioPharma, Xencor, and Standard BioTools.

The report indicates that Johnson & Johnson holds sole investment discretion over these shares, and no put or call option positions are included. For each holding, the filing provides the number of shares and the market value. Notable positions include roughly 2.45 million shares of Protagonist Therapeutics, 4.02 million shares of CVRx, and 1.97 million shares of Contineum Therapeutics. Several of the listed companies are clinical-stage or commercial-stage life sciences firms, reflecting a portfolio concentrated in the biopharmaceutical sector.